The specific aim of this application is to continue the work of accruing patients to clinical research protocols in order to facilitate determinations regarding the most effective treatment course for cancer therapy. The long-term objectives are to decrease the devastating effects of cancer; to provide Ozark residents with access to state of the art cancer therapy; to facilitate the transfer of technology to physicians in the region; and, to develop participation in cancer control research. To date the Ozarks Regional CCOP has accrued 239 patients to NCI approved protocol in the CCOP II grant period. The CCOP has engaged in many educational programs for Springfield and outlying physicians regarding these protocols. The CCOP effort to incorporate highly trained community oncologists in clinical research increase the involvement of minority and underserved populations in clinical research. The Ozarks region, southwest Missouri and northern Arkansas, is populated by a significant number of the elderly. Over 15% of the catchment area's population is over 65 years of age. Since many of these people are expected to remain on fixed incomes, this is essentially a medically underserved area. There are currently five positions at the CCOP office. These employees include two full-time registered nurses, two part-time registered nurses and one coordinator. An organized centrally located data management system, with computer support is available to the Ozarks regional CCOP. The CCOP personnel have a designated liaison at each consortium hospital with whom they may work. Each R.N. data manager is assigned to a specific physician's office, of a specified length of time. This facilitates communication among the physician affiliates. The Ozarks Regional CCOP will continue to expand the capability of physicians to reach more cancer patients with the benefit of research protocols. The CCOP seeks to reduce cancer incidence, morbidity and mortality by accelerating the transfer of newly developed cancer treatment to widespread community application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045560-06
Application #
3558685
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1987-08-15
Project End
1993-05-31
Budget Start
1992-06-01
Budget End
1993-05-31
Support Year
6
Fiscal Year
1992
Total Cost
Indirect Cost
Name
St. John's Regional Health Center
Department
Type
DUNS #
076256809
City
Springfield
State
MO
Country
United States
Zip Code
65804
Ahmed, Amina; Deng, Wei; Tew, William et al. (2018) Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol 150:300-305
Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8

Showing the most recent 10 out of 157 publications